Developmental therapeutics
Invited discussant abstracts 359O and 360O_PR
Date
08 Oct 2016Session
Developmental therapeuticsPresenters
Christian RolfoAuthors
C.D. RolfoAuthor affiliations
- Oncology Unit, U.Z.A. University Hospital Antwerp, 2650 - Edegem/BE
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
3058 - A phase I study evaluating DLYE5953A, an antibody-drug conjugate targeting the tumor-associated antigen lymphocyte antigen 6 complex locus E (Ly6E), in patients (Pts) with solid tumors
Presenter: Shanu Modi
Session: Developmental therapeutics
Resources:
Abstract
Slides
Webcast
3319 - 89Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation in a dose-dependent manner and role of IL-2 receptor-binding
Presenter: Catharina Menke-van der Houven van Oordt
Session: Developmental therapeutics
Resources:
Abstract
Invited discussant abstracts 357O and 358O
Presenter: Christophe Massard
Session: Developmental therapeutics
Resources:
Slides
Webcast
1623 - First-in-human study of AC0010, a novel irreversible, mutant-selective EGFR inhibitor in patients with 1st generation EGFR TKI-resistant non-small cell lung cancer (NSCLC)
Presenter: Li Zhang
Session: Developmental therapeutics
Resources:
Abstract
3198 - Phase I study of the pan-fibroblast growth factor receptor (FGFR) inhibitor BAY 1163877 with expansion cohorts for subjects based on tumor FGFR mRNA expression levels
Presenter: Markus Joerger
Session: Developmental therapeutics
Resources:
Abstract
3573 - Interim results from the completed first-in-human phase I dose escalation study evaluating MP0250, a multi-DARPin® blocking HGF and VEGF, in patients with advanced solid tumors
Presenter: Mark Middleton
Session: Developmental therapeutics
Resources:
Abstract
3758 - TAX-TORC: An investigator initiated phase I study combining the dual mTORC1/2 inhibitor AZD2014 in combination with weekly paclitaxel in high-grade serous ovarian cancer
Presenter: Udai Banerji
Session: Developmental therapeutics
Resources:
Abstract
3018 - Molecular imaging of PgP/BCRP inhibition at the blood brain barrier using elacridar and [11C]erlotinib PET
Presenter: Remy Verheijen
Session: Developmental therapeutics
Resources:
Abstract
Invited discussant abstracts 361PD, 362PD and 363PD
Presenter: Irene Braña
Session: Developmental therapeutics
Resources:
Slides
Webcast
4011 - Anti-tumor activity of PEGylated human IL-10 (AM0010) in renal cancer alone and in combination with anti-PD1
Presenter: Aung Naing
Session: Developmental therapeutics
Resources:
Abstract
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.